


NEOANTIGEN

Summit2017

Supercharging Immunotherapies
& Cancer Vaccines



Day One

Wednesday, November 15, 2017

08.00 Breakfast & Registration

09.00 Chair's Opening Remarks

Roman Yelensky, EVP & CTO, Gritstone Oncology

Neoantigen Targeting for Enhanced Efficacy

09.30 Neoantigens as Targets in Oncology: A Compelling Case

Jim Johnston, Executive Director, Research , Amgen

10.00 Targets Matter: What Decides a Peptide is an Antigen? Software or the Patient's T Cells?

Pamela Carroll, SVP, Immuno- Oncology , Genocea Biosciences

10.30 Morning Refreshments & Speed Networking

Improving Methods for Neoantigen Identification

11.30 NGS Solutions for Immunonocology

Donna Nichol, Oncology Science Liaison, Translational Science & Diagnostics, Personal Genome Diagnostics

12.00 Open Source Tools and Models for Neoantigen Prediction

Alex Rubinsteyn, Researcher, Hammerbacher Lab , Mount Sinai

12.30 Accelerating the Development of Personalized Cancer Immunotherapy: Mass Spectrometry based Immunoepitidomics

Michal Bassani- Sternberg, Director, Immunoepitidomics , CHUV

13.00 Lunch Networking

14.00 Discovering Real Neoantigens through the XPRESIDENT® Mass Spectrometry Platform

Harpreet Singh, CSO & Co-Founder , Immatics Biotechnologies

NEOANTIGEN Summit2017

Supercharging Immunotherapies
& Cancer Vaccines




Neoantigen Prioritization & Immune Monitoring to Ensure Selection of Most Potent Neoantigens

- 14.30 From Sample to Neoantigens for Vaccines: Key Challenges and Solutions**
Richard Chen, CSO, Personalis
- 15.00 Targeting the Broad Spectrum of Patient-Specific Tumor Neoantigens without the Need to Identify Them**
Mark DeBenedette, Director of Immunology, Argo Therapeutics
- 15.30 Afternoon Refreshments & Poster Session**
- 16.30 Personalized Liquid Biopsy and its Biopharma Applications**
Eric Lindquist, VP, Pharma Business Development, Natera
- 17.00 Neoantigens as Prognostic and Diagnostic Tools**
David Kaufman, Head, Translational Oncology , Merck
- 17.30 Chairman's Closing Remarks**
Roman Yelensky, EVP & CTO , Gritstone Oncology
- 17.45 Close of Day 1**

NEOANTIGEN Summit2017

Supercharging Immunotherapies
& Cancer Vaccines



Day Two Thursday, November 16, 2017

08.00 Breakfast & Registration

09.00 Chair's Opening Remarks

Martin Bonde, CEO, Vaccibody

Ensuring Successful Delivery of Neoantigen Therapies

09.30 Neoantigens as Targets for Multiple Therapeutic Approaches

Marit van Buuren, PhD, Lab Head, Immunology, Neon Therapeutics

10.00 Vaccination with Great Ape Derived Adenovectors Encoding for Cancer Neoantigens Shows Potent Synergy with Immunomodulators

Elisa Scarselli, CSO, Nouscom

10.30 Neoantigens are the Achilles' Heel of Cancer

Laurence Cooper, CEO, ZIOPHARM Oncology

11.00 Meeting the Challenges of Personalized Medicine

May Pidding, Director, Business Development, Ichor Medical Systems
James Brown, VP, Corporate Development, Aldevron

11.30 Morning Refreshments & Networking

Clinical Trials Case Studies

12.00 Targeting Patient-Specific Neoantigens using a Personalized, Live-Attenuated Double Deleted *Listeria monocytogenes* (pLADD) Immunotherapy

Amanda Enstrom, Associate Director, Aduro Biotech

12.30 Exploiting NGS for Clinical Individualized Neoantigen Cancer Vaccines

John Castle, CSO, Achilles Therapeutics

13.00 Synthetic Long Peptides for Neoantigen-Specific Immunotherapy of Cancer:

Ronald Loggers, CEO, ISA Pharmaceuticals

13.30 Lunch & Networking

14.30 Turning Up the Heat on Pancreatic Cancer: Overcoming an Immunologically Cold Landscape

Heather Kinkead, Postdoctoral Fellow, Elizabeth Jaffee Lab, Johns Hopkins School of Medicine

NEOANTIGEN Summit2017

Supercharging Immunotherapies
& Cancer Vaccines



Vaccine Manufacturing

- 15.00 Development of Safe, Efficacious and Cost-Efficient Cancer Neoantigen Vaccines**
Agnete Fredrickson, CSO , Vaccibody

- 15.30 Chairman's Closing Remarks**
Martin Bonde, CEO, Vaccibody

- 15.45 Close of Congress**